Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Ambu A/S
  6. News
  7. Summary
    AMBU B   DK0060946788


Delayed Quote. Delayed Nasdaq Copenhagen - 10/22 10:59:54 am
186.05 DKK   -0.08%
10/15AMBU A/S : Q4 Aide-mémoire file_download
10/05AMBU A/S : Preliminary results for full year 2020/21 (no. 1)
10/05Ambu Announces Preliminary Revenue Results for the Year 2021
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ambu A/S : commits to Science Based Targets initiative

08/30/2021 | 10:12am EDT

AUG. 2021

Ambu commits to Science Based Targets initiative
add Details
In efforts to strengthen our climate commitment, Ambu has transformed our carbon reduction goal to a science-based target.
Ambu has signed up to the Science Based Target Initiative (SBTi) and committed to setting carbon emission targets which meet the goals of the Paris Agreement.

"At a time where the effects of climate change are increasingly evident, we recognize that an environmental focus is critical. As a global supplier of single-use medical devices, we feel a responsibility to forge the way with ambitious targets and concrete sustainable practices. Committing to the Science Based Targets initiative is a natural next step for Ambu as we raise the bar on our carbon reduction target, not only in our own operations, but across our entire vale chain, "says Lene Møldrup, Director, ESG.

Ambu commits to the ambitious 1.5-degree target
Research has shown that in order to avoid irreversible climate damage, the global temperature rise must not exceed 1.5°C.
Ambu has chosen to sign up for the most ambitious target of 1.5°C science-based reduction. This means that Ambu will have to reduce carbon emissions across its value chain in line with what is needed to limit a global temperature rise to 1.5°C above pre-industrial levels.

Ambu will employ a three-step strategy to reduce CO2 emissions from its own operations:

Ambu will have a continuous focus on minimizing carbon emissions from production sites through energy efficiency measures.
Ambu will invest in Renewable Energy Certificates. We will focus on new installations and look for suppliers who offer a degree of additionality. Additionality ensures an expansion of renewable energy production sites.
Ambu will work towards establishing power purchase agreements in the countries where we have production facilities in order to ensure additionality and expansion of renewable energy production.
The commitment to SBTi is a part of Ambu's larger ESG strategy to grow sustainably and continuously work towards ways to protect our planet.


The Science Based Targets initiative
The SBTi is a partnership between the Carbon Disclosure Project, the United Nations Global Compact, World Resources Institute (WRI) and the Worldwide Fund for Nature (WWF).

The latest climate science sends a clear warning that we must dramatically curb temperature rise to avoid the catastrophic impacts of climate change. Science-based targets show companies how much and how quickly they need to reduce their greenhouse gas (GHG) emissions to prevent the worst effects of climate change.

Globally, nearly one thousand companies are leading the transition to a net-zero economy by setting emissions reduction targets grounded in climate science through the SBTi.

Targets are considered science-based if they are in line with what the latest climate science deems necessary to meet the goals of the Paris Agreement - limiting global warming to well-below 2°C above pre-industrial levels and pursuing efforts to limit warming to 1.5°C. (Source: sciencebasedtargets.org/about-us)



Ambu A/S published this content on 30 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 August 2021 14:11:01 UTC.

© Publicnow 2021
All news about AMBU A/S
10/15AMBU A/S : Q4 Aide-mémoire file_download
10/05AMBU A/S : Preliminary results for full year 2020/21 (no. 1)
10/05Ambu Announces Preliminary Revenue Results for the Year 2021
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
09/30AMBU A/S : Financial calendar for 2021/22 (no.19)
09/22AMBU A/S : European clearance of Ambu's combined single-use bronchoscope and sampling syst..
08/30AMBU A/S : commits to Science Based Targets initiative
08/24AMBU A/S : Capital increase in connection with exercise of warrants (no. 18)
08/18AMBU A/S : single-use duodenoscope obtains CE mark
08/18AMBU A/S : European market clearance for new generation of single-use endoscopic device fr..
More news
Analyst Recommendations on AMBU A/S
More recommendations
Sales 2021 4 020 M 630 M 630 M
Net income 2021 258 M 40,4 M 40,4 M
Net Debt 2021 586 M 91,8 M 91,8 M
P/E ratio 2021 180x
Yield 2021 0,18%
Capitalization 47 204 M 7 382 M 7 392 M
EV / Sales 2021 11,9x
EV / Sales 2022 10,2x
Nbr of Employees 4 500
Free-Float 65,8%
Chart AMBU A/S
Duration : Period :
Ambu A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMBU A/S
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 8
Last Close Price 186,05 DKK
Average target price 188,50 DKK
Spread / Average Target 1,32%
EPS Revisions
Managers and Directors
Juan-José Gonzalez Chief Executive Officer
Michael Højgaard CFO, EVP-Global Finance, IT & Investor Relations
Jørgen Jensen Chairman
Måns Eskil Barsne Executive VP-Global Research & Development
Henrik Ankjær Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
AMBU A/S-29.31%7 382
MEDTRONIC PLC5.08%165 656
DEXCOM, INC.53.24%54 815